Venture funds are expanding throughout Asia, and government groups are establishing funds to draw business, but there are also signs that Asian pharmaceutical firms are looking to invest in Western startups and are turning their gaze beyond their own borders
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.
Vera is the first company to report Phase III data for a dual inhibitor of APRIL and BAFF in IgA nephropathy. Atacicept provided a 42% placebo-adjusted reduction in proteinuria.
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
